NCT06872112View on ClinicalTrials.gov

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2029

Conditions

Pulmonary Arterial Hypertension (PAH)

Interventions

DRUG

Artesunate

Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors

lead

Joseph C. Wu

OTHER